The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma
2 Vues
• 07/18/23
0
0
Intégrer
administrator
Les abonnés
Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires